SAN DIEGO and PENNINGTON, N.J., Jan.
22, 2019 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced that it will host a 2019 Business
Outlook Conference Call and audio webcast on Friday, February
1, 2019 at 9:00 a.m. ET. The Company will provide a
clinical update from its KEYNOTE-695 study, an overview of its
recently announced collaboration registrational-enabled cervical
cancer study with the Gynecologic Oncology Group (GOG) Foundation,
as well as a review of key value generating milestones the Company
expects to achieve in 2019.
To access the live conference call, please dial (844) 562-3893
(domestic) or (409) 220-9946 (international) at least five minutes
prior to the start time, and refer to conference ID
4067388. An accompanying presentation will be referenced
during the conference call and can be accessed under "Events and
Presentations" in the Investors section of OncoSec's website
at ir.oncosec.com. A replay will be available shortly
after the conference call and can be accessed for 30 days following
the call.
About OncoSec Medical Incorporated
OncoSec is a
clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy platform – TAVO™ (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the
body. OncoSec has built a deep and diverse clinical pipeline
utilizing TAVO™ as a potential treatment for
multiple cancer indications either as a monotherapy or in
combination with leading checkpoint inhibitors; with the latter
potentially enabling OncoSec to address a great unmet medical need
in oncology: anti-PD-1 non-responders. Results from recently
completed clinical studies of TAVO™ have
demonstrated a local immune response, and subsequently, a systemic
effect as either a monotherapy or combination treatment
approach. In addition to TAVO™, OncoSec is
identifying and developing new DNA-encoded therapeutic candidates
and tumor indications for use with its
ImmunoPulse® platform.
CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations
(212) 362-1200
will@sternir.com
Media Relations:
Michael Lampe
Scient Public Relations, Inc.
(484) 575-5040
michael@scientpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-2019-business-outlook-conference-call-on-february-1-2019-300781783.html
SOURCE OncoSec Medical Incorporated